Chk2 (CHEK2) Human shRNA Plasmid Kit (Locus ID 11200)

CAT#: TL320655

CHEK2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 11200
• Synonyms: CDS1; CHK2; hCds1; HuCds1; LFS2; PP1425; RAD53
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol (34 ug/ml)
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: CHEK2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 11200). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_001005735, NM_001257387, NM_007194, NM_145862, NM_001349956, NM_007194.1, NM_007194.2, NM_007194.3, NM_001005735.1, NM_145862.1, NM_145862.2, NM_001257387.1, BC004207, BC004207.2, BM838597, NM_007194.4, NM_001005735.2, NM_001257387.2
• UniProt ID: O96017
• Summary: In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).